Drug manufacturer Gilead told the National Association of Community Health Centers yesterday that NACHC’s condemnation last month of Gilead’s new conditions on 340B contract pharmacy pricing on its branded hepatitis C treatments “seem to represent a misunderstanding of this integrity
…
Drug manufacturer Johnson & Johnson’s new conditions on 340B-purchased drugs when hospitals use contract pharmacies apparently apply also to hospitals’ non-340B-purchased “own use” drugs, the group Ryan White Clinics for 340B Access has told its members.
J&J has not responded
…
Ryan White Clinics for 340B Access (RWC-340B) and its management services consultant have chosen Trent Smith, a former manager and director in both the nonprofit and for-profit sectors, to be RWC-340B’s new managing director.
RWC-340B announced the hiring last week.
…
The National Association of Community Health Centers (NACHC) told drug manufacturer Gilead this morning its new conditions on 340B contract pharmacy pricing on its branded hepatitis C treatments are “unconscionable,” “appalling,” “wrongheaded,” and “the latest example of corporate greed from
…
HIV/AIDS clinics and hospitals that participate in the 340B program are condemning drug manufacturer Gilead’s new conditions on 340B pricing on its branded hepatitis C treatments when covered entities use contract pharmacies.
Ryan White Clinics for 340B Access (RWC-340B) said
…
Non-hospital 340B covered entities have formed a group called 340B Grantees to fight on their own behalf on legislation, in courts, and perhaps in politics at the federal and state levels.
340B Grantees hasn’t formally announced itself yet and is
…
340B provider and drug industry stakeholders joined yesterday in congratulating U.S. Public Health Service Lt. Cmdr. Emeka Egwim on his selection as Director of the U.S. Office of Pharmacy Affairs, the federal agency that runs the 340B drug pricing program.
…
The National Rural Health Association (NRHA) asked U.S. Health and Human Services (HHS) Secretary Xavier Becerra this week to act against drug manufacturers that deny 340B pricing when covered entities use contract pharmacies.
NRHA CEO Alan Morgan also urged Becerra
…
U.S. Health and Human Services (HHS) Secretary Xavier Becerra said yesterday that “we’re going to continue to fight” drug manufacturers that restrict 340B pricing when covered entities use contract pharmacies “because it’s the law.”
Becerra’s Feb. 14 remarks about manufacturers’
…
America’s Essential Hospitals and 340B Health yesterday denounced GlaxoSmithKline’s (GSK) new restrictions on 340B pricing when hospitals use contract pharmacies. Pharmaceutical Research and Manufacturers of America (PhRMA) said this morning it will keep pushing for “much needed changes” to
…*Sign up for news summaries and alerts from 340B Report